Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $49

Benzinga Newsdesk www.benzinga.com Positive 85.6%

Neg 0% Neu 0% Pos 85.6%

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $48 to $49.